MAPT and Alzheimer disease: Mounting evidence indicates that when GSK3α/β is hyperactivated, it promotes Tau hyperphosphorylation and disrupts several neurometabolic activities during the development of AD (Chauhan et al., 2022; Wu et al., 2022).